LINCOLN, NE, April 15 /PRNewswire/ - The acceptance of Peros' oral delivery platform and vaccine facility by the USDA marks another significant achievement by Benchmark Biolabs, a full service biopharmaceutical product development firm.
Benchmark Biolabs designed, constructed and oversees the operation and management of the Peros production facility which is co-located on Benchmark's R&D and manufacturing biotechnology campus in Lincoln, NE.
By obtaining approval by the USDA, Peros, a pioneering biotechnology company that has developed unique natural product formulation methods enabling oral delivery of biopharmaceutical compounds, is now well positioned to begin product commercialization of its oral delivery platform.
"Had it not been for Benchmark's stage-gated "BEAM(TM)" approach to our project from validation to licensure, our technology would have been yet another promising biotech discovery that would never have reached its commercial potential.", stated Dr. Grant Vandenberg, CSO and Founder of Peros.
Benchmark and Peros are excited to offer this first-in-class oral delivery technology platform that will significantly enhance the actual value of vaccines. The licensed platform offers a labor minimizing, practical method for oral delivery of prophylactic and therapeutic products for the livestock industry as well as traditional animal health company opportunities to expand the oral enablement of the industry as a whole.
"Benchmark's mission is to design and implement, with our clients, an efficient product development process - delivering critical expertise, technologies, facilities, ideas and services, in a seamless and integrated offering", added Tom Overbay, Vice-President of Business Development for Benchmark Biolabs.
Peros' licensure marks another significant and innovative first
obtained by Benchmark over their 11-year history. At the Benchmark campus
there are now three licensed manufacturing facilities wh
|SOURCE Benchmark Biolabs|
Copyright©2008 PR Newswire.
All rights reserved